Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.34 |
| ▸ | PDE4A | P27815 | 6/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | PDE9A | O76083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4725113 | 1.00 | LRRK2 (0.35) | LRRK2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6531596 | 0.91 | PDE4D (0.33) | LRRK2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL20506941 | 0.90 | MKNK2 (0.35) | PDE4DPDE4APDE4BPDE4CGRM5 | |
| SCHEMBL3452211 | 0.90 | KAT2B (0.41) | LRRK2KAT2BBAZ2BFFAR2GRM5 | |
| SCHEMBL17610612 | 0.88 | — | — | |
| SCHEMBL20819721 | 0.86 | — | — | |
| SCHEMBL6531967 | 0.83 | KAT2B (0.33) | KAT2BBAZ2BPDE9A | |
| SCHEMBL709427 | 0.80 | HRH1 (0.35) | — | |
| SCHEMBL232553 | 0.77 | HRH1 (0.33) | PDE4DPDE4APDE4BPDE4CPDE9A | |
| SCHEMBL676963 | 0.77 | PDE9A (0.34) | PDE4DPDE4APDE4BPDE4CPDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016041470-A1 | SGLT-2 INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2016-03-24 | — | — | WO | claimed |
| US-10562915-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180273547-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2018-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562915-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | LRRK2 657/4885PDE4D 3150/4885PDE4A 2738/4885 |
| US-20180273547-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | LRRK2 657/4885PDE4D 3150/4885PDE4A 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.